Pfizer makes haste to go EZ
The company sticks with EZH2, despite others adding EZH1 inhibition.
ASH 2023 – a new EZ battle shapes up
Daiichi aims to expand valemetostat into a new use, but Haihe Biopharma isn't far behind.
The company sticks with EZH2, despite others adding EZH1 inhibition.
Daiichi aims to expand valemetostat into a new use, but Haihe Biopharma isn't far behind.
